Exploring Today’s ALS Treatment Options & Emerging Research
The Ongoing Challenge of ALS
Amyotrophic lateral sclerosis (ALS) remains one of the most challenging neurodegenerative diseases to treat. Characterized by progressive motor neuron loss in the brain and spinal cord, ALS leads to muscle weakness, paralysis, and ultimately respiratory failure.
Despite decades of research, therapeutic breakthroughs have been incremental. Today, only a handful of approved drugs exist, each offering modest benefit. Yet, ALS research is evolving rapidly, with new therapeutic modalities, biomarker development, and precision approaches showing promise. Explore the current treatment options and emerging research shaping the future of ALS care.
Current Standard of Care for ALS
A small number of FDA-approved drugs, combined with multidisciplinary care strategies, provide the foundation for ALS management and symptom relief today.
FDA-Approved Medications
The therapeutic arsenal for ALS currently includes three drugs, each targeting different aspects of disease biology:
- Qalsody® (tofersen): Qalsody is an antisense oligonucleotide therapy approved in 2023 for ALS caused by mutations in the SOD1 gene. Delivered via intrathecal injection, it works by reducing the production of toxic SOD1 proteins that drive motor neuron damage. Because it is mutation-specific, Qalsody is only effective in patients with confirmed SOD1 ALS.
- Radicava® (Edaravone): First approved as an IV formulation in 2017 and later as an oral suspension in 2022, Radicava is designed to slow functional decline by reducing oxidative stress. The drug neutralizes reactive oxygen species—unstable molecules that contribute to neuronal injury and ALS progression.
- Riluzole (Rilutek, Tiglutik®, and Exservan™): Riluzole was the first FDA-approved ALS therapy and remains a foundation of treatment. Available in tablet, thickened liquid, and oral film formulations, riluzole reduces glutamate release, thereby limiting excitotoxicity—a process believed to contribute to motor neuron death.
- Nuedexta® (Dextromethorphan HBr and Quinidine Sulfate): Nuedexta is indicated for pseudobulbar affect, a condition marked by uncontrolled laughing or crying. In ALS, it may also improve bulbar function, which affects speech and swallowing, offering symptomatic benefit even for patients without pseudobulbar affect.
Multidisciplinary Care
Pharmacological therapy is only part of ALS management. Evidence shows that multidisciplinary ALS clinics—integrating neurology, pulmonology, nutrition, physical therapy, and palliative care—improve both survival and quality of life. Respiratory and nutritional support, including non-invasive ventilation and percutaneous feeding tubes, remains a critical intervention. Assistive technologies, from speech devices to mobility aids, play an equally important role in prolonging independence.
Symptom Management & Quality of Life
ALS is as much about managing symptoms as it is about targeting disease progression. Interventions include:
- Respiratory Support: Non-invasive ventilation improves survival and quality of life in advanced disease.
- Nutritional Support: PEG feeding addresses dysphagia and prevents malnutrition, prolonging survival.
- Communication Aids: Eye-tracking software and brain-computer interfaces provide independence as speech declines.
- Palliative Care: Pain management, psychosocial support, and advanced care planning are increasingly recognized as core to ALS care.
While these approaches do not alter disease biology, they directly impact patient experience and outcomes.
Emerging Research & Experimental Approaches
Despite limited current therapies, the ALS research pipeline has never been more active. Advances in genetics, cell biology, and biomarker science are driving a new wave of experimental approaches that move beyond symptom management toward disease modification.
Gene Therapies
The genetic underpinnings of ALS, linked to mutations such as SOD1, C9orf72, FUS, and TARDBP, have spurred gene-targeted therapies. Notable advances include:
- Tofersen: An antisense oligonucleotide (ASO) therapy targeting SOD1. Clinical trial data demonstrated significant reductions in neurofilament light chain, a biomarker of neuronal damage, even if clinical outcomes were more modest. Tofersen gained FDA approval under accelerated pathways, marking the first gene-specific ALS therapy.
- C9orf72-Targeted Therapies: Several ASO approaches are in development, though early trials have faced safety and efficacy challenges.
Gene therapies underscore the move toward personalized medicine in ALS, with the potential to target underlying pathophysiology rather than downstream symptoms.
Stem Cell Therapies
Stem cell-based interventions aim to replace or protect degenerating motor neurons. Strategies under investigation include transplantation of neural progenitor cells and mesenchymal stem cells engineered to secrete neurotrophic factors. While early studies demonstrate safety and biological activity, efficacy data remain preliminary. Delivery methods, engraftment efficiency, and long-term safety represent ongoing hurdles.
Biomarker Development
A central barrier to ALS research has been the lack of reliable biomarkers. Traditional measures such as clinical scales and survival endpoints are slow and variable, complicating trial design. Biomarkers can accelerate therapeutic development by enabling earlier diagnosis, patient stratification, and pharmacodynamic readouts.
Key advances include:
- Neurofilament Light Chain (NfL): The most validated ALS biomarker, correlating with disease severity and progression.
- Imaging Biomarkers: MRI-based measures of corticospinal tract integrity are under investigation.
- Neuron-Derived Extracellular Vesicles (nEVs): An emerging frontier, nEVs act as “liquid biopsies” of the brain, carrying molecular signatures of neuronal health. Compared to total EVs or serum measures, nEVs offer higher specificity, enabling clearer insights into disease biology from just microliters of plasma.
These biomarker advances promise not only to enhance trial efficiency but also to support more personalized approaches to care.
Novel Drug Approaches
Beyond gene and cell therapies, a wide range of investigational compounds target neuroinflammation, protein misfolding, and mitochondrial dysfunction. Examples include:
- Anti-Inflammatory Agents: Targeting microglial activation and immune pathways.
- Protein Homeostasis Modulators: Addressing TDP-43 aggregation and proteostasis failure.
- Combination Strategies: Recognizing ALS as multifactorial, researchers are increasingly testing multi-target therapies.
The Future of ALS Research
The ALS research ecosystem is more dynamic than ever, driven by patient advocacy, regulatory flexibility, and scientific innovation. Several trends will shape its future:
- Precision Medicine: Stratifying patients by genetic and biomarker-defined subgroups.
- Adaptive Trial Designs: Innovative frameworks such as platform trials (e.g., HEALEY ALS Platform Trial) streamline the evaluation of multiple therapies.
- Data Integration: Combining molecular, imaging, and digital biomarkers for a multidimensional view of disease.
- Collaborative Networks: Partnerships between academia, industry, regulators, and patient groups are accelerating therapeutic pipelines.
While challenges remain, particularly disease heterogeneity and small patient populations, ALS research is entering an era of unprecedented possibilities.
ALS Research Is Entering a New Era of Precision & Possibility
For decades, ALS treatment options have been limited, and therapeutic gains have been incremental. Today, however, the convergence of gene therapies, stem cell approaches, and advanced biomarker platforms is redefining what is possible. Even as current drugs offer modest benefit, the future holds promise for more precise, disease-modifying therapies.
Progress in ALS research underscores a broader truth: success requires not just new drugs, but new ways of measuring disease and understanding neuronal health. The next breakthroughs may come not only from molecules, but from the biomarkers that reveal their impact.
At NeuroDex, we provide brain-specific biomarker research services that bring clarity and confidence to ALS research. By isolating neuron-derived signals from blood, we help biopharma, CROs, and academic teams accelerate discovery, validate therapies, and move closer to transformative treatments. If you’re working to advance ALS research, partner with us to measure the brain more clearly.
